BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kimura T, Snijder R, Sugitani T. Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: A nationwide real-world analysis using a large hospital-based administrative dataset. J Infect Chemother 2019;25:615-20. [PMID: 30987950 DOI: 10.1016/j.jiac.2019.03.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Watanabe K, Shimodaira Y, Takahashi S, Fukuda S, Koizumi S, Matsuhashi T, Iijima K. Potent Acid Suppression With Vonoprazan vs Proton Pump Inhibitors Does Not Have Higher Association With Clostridioides difficile Infection. Am J Gastroenterol 2021;116:1632-7. [PMID: 33989224 DOI: 10.14309/ajg.0000000000001309] [Reference Citation Analysis]
2 Alrahmany D, Ereshefsky BJ, El Nekidy WS, Harb G, Pontiggia L, Ghazi IM. Risk Factors for Recurrence of Clostridioides difficile in Hospitalized Patients. J Infect Public Health 2021;14:1642-9. [PMID: 34627059 DOI: 10.1016/j.jiph.2021.09.016] [Reference Citation Analysis]
3 van Rossen TM, Ooijevaar RE, Vandenbroucke-Grauls CMJE, Dekkers OM, Kuijper EJ, Keller JJ, van Prehn J. Prognostic factors for severe and recurrent Clostridioides difficile infection: a systematic review. Clin Microbiol Infect 2021:S1198-743X(21)00552-8. [PMID: 34655745 DOI: 10.1016/j.cmi.2021.09.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 van Prehn J, Reigadas E, Vogelzang EH, Bouza E, Hristea A, Guery B, Krutova M, Norén T, Allerberger F, Coia J, Goorhuis A, van Rossen TM, Ooijevaar RE, Burns K, Scharvik Olesen BR, Tschudin-Sutter S, Wilcox MH, Vehreschild M, Fitzpatrick F, Kuijper EJ; guideline committee of the European Study Group on Clostridioides difficile. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect 2021:S1198-743X(21)00568-1. [PMID: 34678515 DOI: 10.1016/j.cmi.2021.09.038] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 D'Silva KM, Mehta R, Mitchell M, Lee TC, Singhal V, Wilson MG, McDonald EG. Proton pump inhibitor use and risk for recurrent Clostridioides difficile infection: a systematic review and meta-analysis. Clin Microbiol Infect 2021:S1198-743X(21)00035-5. [PMID: 33465501 DOI: 10.1016/j.cmi.2021.01.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Negrut N, Bungau S, Behl T, Khan SA, Vesa CM, Bustea C, Nistor-cseppento DC, Rus M, Pavel F, Tit DM. Risk Factors Associated with Recurrent Clostridioides difficile Infection. Healthcare 2020;8:352. [DOI: 10.3390/healthcare8030352] [Reference Citation Analysis]
7 Negrut N, Bungau S, Behl T, Khan SA, Vesa CM, Bustea C, Nistor-Cseppento DC, Rus M, Pavel FM, Tit DM. Risk Factors Associated with Recurrent Clostridioides difficile Infection. Healthcare (Basel) 2020;8:E352. [PMID: 32967323 DOI: 10.3390/healthcare8030352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Kimura T, Stanhope S, Sugitani T. Excess length of hospital stay, mortality and cost attributable to Clostridioides (Clostridium) difficile infection and recurrence: a nationwide analysis in Japan. Epidemiol Infect 2020;148:e65. [PMID: 32115019 DOI: 10.1017/S0950268820000606] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]